Across TCGA pan-cancer cohorts, TRBV4-2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRBV4-2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRBV4-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRBV4-2 expression acts as an unfavorable survival marker.

LUAD and PRAD are the cancer types where TRBV4-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.288	0.813	<.001	24	view →
PRAD	DFS	Median	All	0.086	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRBV4-2 tumor-vs-normal RNA expression · all TRBV4-2 data types